Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Although it has long been appreciated that ovarian carcinoma subtypes (serous, clear cell, endometrioid, and mucinous) are associated with different natural histories, most ovarian carcinoma biomarker studies and current treatment protocols for women with this disease are not subtype specific. With the emergence of high-throughput molecular techniques, distinct pathogenetic pathways have been identified in these subtypes. We examined variation in biomarker expression rates between subtypes, and how this influences correlations between biomarker expression and stage at diagnosis or prognosis. METHODS AND FINDINGS: In this retrospective study we assessed the protein expression of 21 candidate tissue-based biomarkers (CA125, CRABP-II, EpCam, ER, F-Spondin, HE4, IGF2, K-Cadherin, Ki-67, KISS1, Matriptase, Mesothelin, MIF, MMP7, p21, p53, PAX8, PR, SLPI, TROP2, WT1) in a population-based cohort of 500 ovarian carcinomas that was collected over the period from 1984 to 2000. The expression of 20 of the 21 biomarkers differs significantly between subtypes, but does not vary across stage within each subtype. Survival analyses show that nine of the 21 biomarkers are prognostic indicators in the entire cohort but when analyzed by subtype only three remain prognostic indicators in the high-grade serous and none in the clear cell subtype. For example, tumor proliferation, as assessed by Ki-67 staining, varies markedly between different subtypes and is an unfavourable prognostic marker in the entire cohort (risk ratio [RR] 1.7, 95% confidence interval [CI] 1.2%-2.4%) but is not of prognostic significance within any subtype. Prognostic associations can even show an inverse correlation within the entire cohort, when compared to a specific subtype. For example, WT1 is more frequently expressed in high-grade serous carcinomas, an aggressive subtype, and is an unfavourable prognostic marker within the entire cohort of ovarian carcinomas (RR 1.7, 95% CI 1.2%-2.3%), but is a favourable prognostic marker within the high-grade serous subtype (RR 0.5, 95% CI 0.3%-0.8%). CONCLUSIONS: The association of biomarker expression with survival varies substantially between subtypes, and can easily be overlooked in whole cohort analyses. To avoid this effect, each subtype within a cohort should be analyzed discretely. Ovarian carcinoma subtypes are different diseases, and these differences should be reflected in clinical research study design and ultimately in the management of ovarian carcinoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
World Health Organization Classification of Tumours
Fletcher, C., van den Berg, A., & Molenaar, I. (2002) · Cited by 7,079
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)
McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., & Clark, G. M. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji237 · Cited by 2,162
Shih, I.-M., & Kurman, R. J. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63708-x · Cited by 1,206
du Bois, A. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg036 · Cited by 1,113 · cited 1×
“The dismal response rate of clear cell carcinomas (15%) contrasts sharply with that of high-grade serous (80%), resulting in a lower 5-y survival for clear cell compared with high-grade serous carcinoma in patients with advanced stage tumors (20% versus 30%) [7,8].”
BackgroundWright, G., Tan, B., Rosenwald, A., Hurt, E. H., Wiestner, A., & Staudt, L. M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1732008100 · Cited by 1,040 · cited 1×
“, breast carcinoma and lymphoma [24,25]), and this subtype specific approach to treatment has implications for the design of clinical trials for women with ovarian carcinomas.”
BackgroundGrading Ovarian Serous Carcinoma Using a Two-Tier System
Malpica, A., Deavers, M. T., Lu, K., Bodurka, D. C., Atkinson, E. N., Gershenson, D. M., & Silva, E. G. (2004) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200404000-00009 · Cited by 670 · cited 1×
“The serous subtype was further subdivided into low- and high-grade [11].”
BackgroundLu, K. H., Patterson, A. P., Wang, L., Marquez, R. T., Atkinson, E. N., Baggerly, K. A., Ramoth, L. R., Rosen, D. G., Liu, J., Hellstrom, I., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0409 · Cited by 440 · cited 1×
“For example, CA125 is expressed in most high-grade serous carcinoma, but only in 60% of mucinous and clear cell subtypes, a finding that is consistent with previous studies [26].”
ResultSchwartz, D. R., Kardia, S. L. R., Shedden, K., Kuick, R. D., Michailidis, G. C., Taylor, J. M. G., Misek, D. E., WU, R. T., Zhai, Y., Darrah, D. M., et al. (2002) · PubMed · Cited by 430
Singer, G., Stöhr, R., Cope, L., Dehari, R., Hartmann, A., Cao, D.-F., Wang, T.-L., Kurman, R. J., & Shih, I.-M. (2005) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000146025.91953.8d · Cited by 408 · cited 1×
“The goal of our marker selection was to use proteins that are consistently expressed in ovarian carcinomas and have been reported as prognosticators (p53, p21, Ki-67, PR, WT1) [”
MethodZorn, K. K., Bonome, T., Gangi, L., Chandramouli, G. V. R., Awtrey, C. S., Gardner, G. J., Barrett, J. C., Boyd, J., & Birrer, M. J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0508 · Cited by 376 · cited 1×
“Each of theses subtypes is associated with different genetic risk factors and molecular events during oncogenesis [1,2], and characterized by distinct mRNA expression profiles [3,4].”
Background
Research works printed but not linked: 2
- Swenerton KD 2008 Ovarian carcinoma treatment guidelines of the British Columbia Cancer Agency Available: http://www.bccancer.bc.ca/PPI/TypesofCancer/Ovary/default.htm. Accessed 1 April 2000
- Turbin DA Leung S 2008 GPEC plugin for Image J an image analyzing software Available: http://www.gpec.ubc.ca/index.php?content=software/imagej_plugin/index.php. Accessed 20 April 2008
Cited by
Items 401–500 of 895
Acquired Evolution of Mitochondrial Metabolism Regulated by HNF1B in Ovarian Clear Cell Carcinoma
Yamaguchi, K. D., Kitamura, S., Furutake, Y., Murakami, R., Yamanoi, K., Taki, M., Ukita, M., Hamanishi, J., & Mandai, M. (2021) · Cancers · doi:10.3390/cancers13102413 · Cited by 28
Circulating Exosomal miRNAs as Biomarkers in Epithelial Ovarian Cancer
Shiao, M., Chang, J., Lertkhachonsuk, A., Rermluk, N., & Jinawath, N. (2021) · Biomedicines · doi:10.3390/biomedicines9101433 · Cited by 28
Mhawech-Fauceglia, P. Y., Wang, D., Samrao, D., Godoy, H. E., Ough, F., Liu, S., Pejovic, T. B., & Lele, S. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.06.012 · Cited by 28
Wortmannin enhances cisplatin-induced apoptosis in human ovarian cancer cells in vitro.
Jx, Z., Liu, H., Lv, J., & Xj, Y. (2014) · PubMed · Cited by 28
Kelemen, L. E., Goodman, M. T., McGuire, V. M., Rossing, M. A., Webb, P. M., Köbel, M., Anton‐Culver, H., Beesley, J., Berchuck, A., Brar, S., et al. (2010) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-09-1317 · Cited by 27
“Recent advances in histopathologic typing, based on distinct molecular alterations, have led to more accurate classification of ovarian carcinoma types (5, 6), resulting in a lower prevalence for mucinous and endometrioid ovarian carcinomas than previously thought (9).”
BackgroundSelf-citationShen, F., Zhang, X., Zhang, Y., Ding, J., & Chen, Q. (2017) · Oncotarget · doi:10.18632/oncotarget.20251 · Cited by 27
Roles of apelin/APJ system in cancer: Biomarker, predictor, and emerging therapeutic target
Chen, J., Li, Z., Zhao, Q., & Chen, L. (2022) · Journal of Cellular Physiology · doi:10.1002/jcp.30845 · Cited by 27
Novel Therapeutics in Ovarian Cancer: Expanding the Toolbox
Moufarrij, S., & O'Cearbhaill, R. E. (2023) · Current Oncology · doi:10.3390/curroncol31010007 · Cited by 27
“Cadherin 6 (CDH6), a glycoprotein responsible for rapid internalization and cell-to-cell adhesion, is upregulated in ovarian and renal cancers [44].”
BackgroundTaş, F., Karabulut, S., Serilmez, M., Çiftçi, R., & Duranyıldız, D. (2013) · Tumor Biology · doi:10.1007/s13277-013-1401-z · Cited by 27
Dorn, J., Beaufort, N., Schmitt, M., Diamandis, E. P., Goettig, P., & Magdolen, V. (2014) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2013.865701 · Cited by 27
The Diagnostic and Prognostic Potential of microRNAs in Epithelial Ovarian Carcinoma
Samuel, P., & Carter, D. R. F. (2016) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-016-0242-z · Cited by 27
“Another variable is that the subtypes of EOC are essentially different diseases, and when combining subtypes in various analyses it can affect whether molecular markers correlate with clinical parameters [89].”
BackgroundTea, coffee, and caffeinated beverage consumption and risk of epithelial ovarian cancers
Leung, A., Cook, L. S., Swenerton, K. D., Gilks, C. B., Gallagher, R. P., Magliocco, A. M., Steed, H. L., Köbel, M., Nation, J. G., Brooks-Wilson, A. R., et al. (2016) · Cancer Epidemiology · doi:10.1016/j.canep.2016.10.010 · Cited by 27
Self-citationFurther insight into prognostic factors in endometrial cancer: the new serum biomarker HE4
Capriglione, S., Plotti, F., Miranda, A., Lopez, S., Scaletta, G., Moncelli, M., Luvero, D., Nardone, C. D. C., Terranova, C., Montera, R., et al. (2016) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1266263 · Cited by 27
“Additionally, a recent study revealed that HE4 expression is associated with lymph node metastases in breast cancer [110].”
BackgroundDewan, R., Dewan, A., Jindal, M., & Bhardawaj, M. (2019) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2019.20.4.1103 · Cited by 27
Leung, Y., Llauradó, M., Cameron, A., Da-Anoy, A., Cook, L. S., Hoenisch, J., Ghesquiere, C., Gaillard, S. L., Schmid, J., Dawson, A., et al. (2025) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2025.36.e74 · Cited by 26
“Our results also confirm that FOLR1 expression is not prognostic [23,31,32].”
Self-citationSleep Characteristics and Risk of Ovarian Cancer Among Postmenopausal Women
Liang, X., Harris, H. R., HENDRYX, M. S., Shadyab, A. H., Hale, L. E., Li, Y., Crane, T. E., Feliciano, E. M. C., Stefanick, M. L., & Luo, J. (2020) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-20-0174 · Cited by 26
“Each subtype of ovarian cancer has distinct cells of origin, carcinogenic pathways, histology, and clinical features (8, 26).”
BackgroundTargeting Autophagy in Thyroid Cancer: EMT, Apoptosis, and Cancer Stem Cells
Holm, T. M., Yeo, S. K., Turner, K. M., & Guan, J. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.821855 · Cited by 26
“Cadherin-6 (CDH6) is a type 2, atypical cadherin which is aberrantly reactivated in several cancers (Shimazui et al., 1998; Köbel et al., 2008).”
BackgroundSaner, F. A. M., Takahashi, K., Budden, T., Pandey, A., Ariyaratne, D., Zwimpfer, T. A., Meagher, N. S., Fereday, S., Twomey, L., Pishas, K. I., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3552 · Cited by 26
“Taken together, the relationship between RB1 loss and patient survival seems to be dependent on the histotype and/or the molecular context (85).”
BackgroundSelf-citationSung, C. O., Choi, C. H., Ko, Y. H., Ju, H., Choi, Y., Kim, N., Kang, S. Y., Ha, S. Y., Choi, K., Bae, D., et al. (2013) · Cancer Genetics · doi:10.1016/j.cancergen.2013.04.002 · Cited by 26
Zannoni, G. F., Improta, G., Pettinato, A., Brunelli, C., Troncone, G., Scambia, G., & Fraggetta, F. (2016) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2016-203776 · Cited by 26
The rise of genomic profiling in ovarian cancer
Previs, R. A., Sood, A. K., Mills, G. B., & Westin, S. N. (2016) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2016.1259069 · Cited by 26
“For example, WT1, more frequently expressed in high-grade serous carcinoma [44], and eight other markers, including CDKN2A, DKK1, HNF1B, MDM2, PGR, TFF3, TP53, and VIM, can be used to predict one of five transcriptional subtypes in a retrospective cohort [45].”
BackgroundSingh, N., & Gilks, C. B. (2016) · Histopathology · doi:10.1111/his.13080 · Cited by 26
Self-citationThe prevalence of EBV and CMV DNA in epithelial ovarian cancer
Ingerslev, K., Høgdall, E. V. S., Skovrider‐Ruminski, W., Schnack, T. H., Lidang, M., Høgdall, C. K., & Blaakær, J. (2019) · Infectious Agents and Cancer · doi:10.1186/s13027-019-0223-z · Cited by 26
CHEN, Y., MU, X., Wang, S., Zhao, L., Wu, Y., LI, J., & Li, M. (2012) · Oncology Reports · doi:10.3892/or.2012.2114 · Cited by 26
“Genomic analysis of ovarian cancer identified amplification of WFDC2 and the whey acidic protein locus in a large proportion of epithelial ovarian cancers (1,4,6,9,11).”
BackgroundRendell, A., Thomas-Bland, I., McCuish, L., Taylor, C., Binju, M., & Yu, Y. (2022) · Biomedicines · doi:10.3390/biomedicines10092113 · Cited by 25
“The mutational profiles of every histological subtype are different: HGSC usually carries TP53 mutations, LGSC and mucinous have increased in BRAF and RAS mutations, while endometrioid and ovarian clear cell carcinoma (OCCC) have mutations in ARID1A and PIK3CA [9,10].”
BackgroundCell-Cycle Protein Expression in a Population-Based Study of Ovarian and Endometrial Cancers
Felix, A. S., Sherman, M. E., Hewitt, S. M., Gunja, M. Z., Yang, H., Cora, R. L., Boudreau, V., Ylaya, K., Lissowska, J., Brinton, L. A., et al. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00025 · Cited by 25
Akbarzadeh, M., Rahbarghazi, R., Nabat, E., Movassaghpour, A. A., Shanehbandi, D., Maragheh, B. F. A., Matluobi, D., Brazvan, B., Kazemi, M., Samadi, N., et al. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.12.119 · Cited by 25
Qiu, D., Cai, W., Zhang, Z., Li, H., & Zhou, D. (2019) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-019-05082-3 · Cited by 25
Modelling Epithelial Ovarian Cancer in Mice: Classical and Emerging Approaches
Zakarya, R., Howell, V. M., & Colvin, E. K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21134806 · Cited by 25
Chen, N., Li, Y., Wu, M., Liu, Z., Fu, Y., Kong, Q., Chen, X., Li, H., & Liu, J. (2011) · Experimental Dermatology · doi:10.1111/j.1600-0625.2011.01392.x · Cited by 25
Targeting Src in endometriosis-associated ovarian cancer
Manek, R., Pakzamir, E., Mhawech-Fauceglia, P. Y., Pejovic, T. B., Sowter, H., Gayther, S. A., & Lawrenson, K. (2016) · Oncogenesis · doi:10.1038/oncsis.2016.54 · Cited by 25
Targeting DNA Damage Response Pathway in Ovarian Clear Cell Carcinoma
Wong, O. G., Li, J., & Cheung, A. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.666815 · Cited by 25
Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2
O'Mahony, D. G., Ramus, S. J., Southey, M. C., Meagher, N. S., Hadjisavvas, A., John, E. M., Hamann, U., Imyanitov, E. N., Andrulis, I. L., Sharma, P., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02263-5 · Cited by 24
“molecular and clinical characteristics [4], ovarian cancer histotypes are considered different diseases [5].”
BackgroundExpression of octamer-4 in serous and mucinous ovarian carcinoma
Zhang, J., Li, Y., Zhou, C., Hu, Y., & Chen, H. (2010) · Journal of Clinical Pathology · doi:10.1136/jcp.2009.073593 · Cited by 24
“Different subtypes of epithelial ovarian carcinoma are different diseases and are associated with different genetic risk factors and molecular events during oncogenesis.(25) 26 In conclusion, our data represent the first report of Oct4 expression in serous and mucinous ovarian tumours.”
BackgroundMAP3K3 overexpression is associated with poor survival in ovarian carcinoma
Jia, W., Dong, Y., Lin, T., Pang, L., Ren, Y., Liang, W., Jiang, J., Cheng, G., Zhang, W. J., Yuan, X., et al. (2015) · Human Pathology · doi:10.1016/j.humpath.2015.12.011 · Cited by 24
Bjersand, K., Seidal, T., Poromaa, I. S., Åkerud, H., & Skírnisdóttir, I. (2017) · PLoS ONE · doi:10.1371/journal.pone.0179363 · Cited by 24
Wild-Type Tumor Repressor Protein 53 (TRP53) Promotes Ovarian Cancer Cell Survival
Mullany, L. K., Liu, Z., King, E. R., Wong, K., & Richards, J. S. (2012) · Endocrinology · doi:10.1210/en.2011-2131 · Cited by 23
Mesothelin as a biomarker for ovarian carcinoma: a meta-analysis
Madeira, K., Dondossola, E. R., FARIAS, B. F. D., Simon, C. S., Alexandre, M. C. M., Silva, B. R., & da Rosa, M. I. (2016) · Anais da Academia Brasileira de Ciências · doi:10.1590/0001-3765201620150107 · Cited by 23
Ki67 expression as a predictor of chemotherapy outcome in low-grade serous ovarian cancer
Grabowski, J., Martínez-Vila, C., Richter, R., TAUBE, E. T., Plett, H., Braicu, E. I., & Sehouli, J. (2020) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2019-000976 · Cited by 23
Kang, E. Y., Millstein, J., Popovic, G. C., Meagher, N. S., Bolithon, A., Talhouk, A., Chiu, D. S., Anglesio, M. S., Leung, B., Tang, K., et al. (2021) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-021-03232-0 · Cited by 23
“As we have previously shown, histotype is an effect modifier for biomarker studies and analyses should be stratified by histotype [14].”
BackgroundAberrant MAPK Signaling Offers Therapeutic Potential for Treatment of Ovarian Carcinoma
Colic, E., Patel, P. U., & Kent, O. A. (2022) · OncoTargets and Therapy · doi:10.2147/ott.s361512 · Cited by 23
“Importantly, the molecular alterations that define subtypes of EOC offer the potential for targeted therapies including those subtypes that may respond to RAS/MAPK inhibition.(20) Studies suggest a dualistic model of ovarian carcinogenesis that correlates with the clinical, histopathological, genetic, and molecular fe…”
BackgroundA multivariate model of ErbB network composition predicts ovarian cancer cell response to canertinib
Prasasya, R. D., Vang, K. Z., & Kreeger, P. K. (2011) · Biotechnology and Bioengineering · doi:10.1002/bit.23297 · Cited by 23
“In addition, it has been shown that the serous subtype is predominant in advanced stage EOC (Kobel et al. 2008).”
BackgroundLawrenson, K., Grün, B., & Gayther, S. A. (2012) · Journal of Visualized Experiments · doi:10.3791/4206 · Cited by 23
Zamani, N., Gilani, M. M., Zamani, F., & Zamani, M. H. (2015) · PubMed Central · Cited by 23
Wu, P., Zhou, D., Wang, Y., Lin, W., Sun, A., Wei, H., Fang, Y., Cong, X., & Jiang, Y. (2018) · Oncology Reports · doi:10.3892/or.2018.6947 · Cited by 23
“Previous association analyses between candidate biomarkers and clinical features mainly utilized contingency tables and Fisher's exact test (15,33,34).”
MethodTumors that mimic asbestos-related mesothelioma: time to consider a genetics-based tumor registry?
Kerger, B. D., James, R. C., & Galbraith, D. A. (2014) · Frontiers in Genetics · doi:10.3389/fgene.2014.00151 · Cited by 23
“…positive calretinin, CK7, and WT-1, with negative CEA) and cellular characteristics (epithelioid, poorly differentiated) are commonly seen for both mesothelioma and PSC (Fox, 1993; Schorge et al., 2000; Shimizu et al., 2000; Al-Hussaini et al., 2004; McCoubrey et al., 2005; Kobel et al., 2008).”
Backgroundp21 promotes oncolytic adenoviral activity in ovarian cancer and is a potential biomarker
Flak, M. B., Connell, C. M., Chelala, C., Archibald, K. M., Salako, M. A., Pirlo, K. J., Lockley, M., Wheatley, S. P., Balkwill, F. R., & McNeish, I. A. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-175 · Cited by 23
“In the serous sub-type, p21 expression is frequently lost [46] and this appears to be a poor prognostic factor [47].”
Klein, K., Oualkacha, K., Lafond, M.-H., Bhatnagar, S., Tonin, P. N., & Greenwood, C. M. T. (2016) · Frontiers in Genetics · doi:10.3389/fgene.2016.00137 · Cited by 22
“Our results were consistent with earlier reports associating high-grade serous ovarian carcinomas harboring p53 null mutations with poorer overall outcome (Kobel et al., 2008) or distant metastasis (Sood et al., 1999).”
Aptamers as potential therapeutic agents for ovarian cancer
Henri, J., MacDonald, J. P., Strom, M., Duan, W., & Shigdar, S. L. (2017) · Biochimie · doi:10.1016/j.biochi.2017.12.001 · Cited by 22
Antioxidants and Therapeutic Targets in Ovarian Clear Cell Carcinoma
Amano, T., Murakami, A., Murakami, T., & Chano, T. (2021) · Antioxidants · doi:10.3390/antiox10020187 · Cited by 22
“ECs display estrogen and progesterone receptors [10] and are not significantly associated with antioxidant molecules such as hepatocyte nuclear factor 1 homeobox B (HNF1B) or mitochondrial superoxide dismutase (SOD2).”
BackgroundHE4 protein and SMRP: Potential novel biomarkers in ovarian cancer detection
Fritz-Rdzanek, A., Grzybowski, W., Beta, J., Durczyński, A., & Jakimiuk, A. J. (2012) · Oncology Letters · doi:10.3892/ol.2012.757 · Cited by 22
Falkenthal, T. E. H., Nymoen, D. A., Holth, A., Brusegard, K., Flørenes, V. A., Kærn, J., Trope, C. G., & Davidson, B. (2012) · Human Pathology · doi:10.1016/j.humpath.2012.08.002 · Cited by 22
Skírnisdóttir, I., Seidal, T., & Åkerud, H. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3333 · Cited by 22
“A semi-quantitative analysis (15) was used and the stains were graded as negative, +, ++ and +++ for p53, VEGF-A, VEGF-R1 and VEGF-R2, and all those markers were dichotomized into negative and positive (+, ++ and +++) cases (16).”
MethodDetecting ovarian cancer using extracellular vesicles: progress and possibilities
Carollo, E., Paris, B., Samuel, P., Pantazi, P., Bartelli, T. F., Dias‐Neto, E., Brooks, S. A., Pink, R. C., & Carter, D. R. F. (2019) · Biochemical Society Transactions · doi:10.1042/bst20180286 · Cited by 22
Epiregulin as a marker for the initial steps of ovarian cancer development
Amsterdam, A., Shezen, E., Raanan, C., Slilat, Y., Ben‐Arie, A., Prus, D., & Schreiber, L. (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.1123 · Cited by 22
Qualitative Age Interactions between Low-grade and High-grade Serous Ovarian Carcinomas
Grimley, P. M., Matsuno, R. K., Rosenberg, P. S., Henson, D. E., Schwartz, A. M., & Anderson, W. F. (2009) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-09-0240 · Cited by 22
“The heterogeneity of ovarian epithelial cancers, including the predominant histologic type of serous ovarian carcinoma (SOC), is well-recognized (1-5).”
BackgroundRahman, M. T., Nakayama, K., Rahman, M., Katagiri, H., Katagiri, A., Ishibashi, T., Ishikawa, M., Iida, K., Nakayama, N., Otsuki, Y., et al. (2012) · PubMed · Cited by 22
Ye, S., Yang, J., You, Y., Cao, D., Huang, H., Wu, M. P., Chen, J., Lang, J., & Shen, K. (2015) · PLoS ONE · doi:10.1371/journal.pone.0133498 · Cited by 22
“The histological subtypes of ovarian cancer are perceived to be distinct diseases, each with distinct clinical and molecular characteristics [2–4].”
BackgroundÖzdemir, D. A., & Usubutün, A. (2016) · Pathology & Oncology Research · doi:10.1007/s12253-016-0040-2 · Cited by 22
Zhu, X., Shijing, Y. O. U., Du, X., Song, K., Lv, T., Zhao, H., & Yao, Q. (2023) · BMC Medical Genomics · doi:10.1186/s12920-023-01435-9 · Cited by 22
Tewari, K. S., & Eskander, R. N. (2013) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s45885 · Cited by 21
Parra‐Herran, C., Bassiouny, D., Vicus, D., Olkhov‐Mitsel, E., Cesari, M., Ismiil, N. D., & Nofech‐Mozes, S. (2018) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001160 · Cited by 21
Metastases to and from the Breast
Bombonati, A., & Lerwill, M. F. (2012) · Surgical pathology clinics · doi:10.1016/j.path.2012.06.004 · Cited by 21
Jönsson, J.-M., Johansson, I., Valentin, M. D., Kimbung, S., Jönsson, M., Bonde, J. H., Kannisto, P., Måsbäck, A., Malander, S., Nilbert, M. C., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107643 · Cited by 21
“Personalized therapy is called for in ovarian cancer particularly since the histopathologic subtypes, as well as tumors with different malignant potential and tumor grade, can be viewed as separate diseases with differences related to both prognosis and treatment response [8–12].”
BackgroundSelenium-Binding Protein 1 (SBP1) autoantibodies in ovarian disorders and ovarian cancer
Yu-Rice, Y., Edassery, S. L., Urban, N. D., Hellström, I., Hellström, K. E., Deng, Y., Li, Y., & Luborsky, J. L. (2016) · Reproduction · doi:10.1530/rep-16-0265 · Cited by 21
Karnezis, A. N., Aysal, A., Zaloudek, C. J., & Rabban, J. T. (2012) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31826a5399 · Cited by 20
Fan, Q., Cheng, J., Qiu, X. Y., Chang, H., & Leung, P. C. K. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.12.097 · Cited by 20
Ambivalent role of pFAK-Y397 in serous ovarian cancer-a study of the OVCAD consortium
Aust, S., Auer, K., Bachmayr-Heyda, A., Denkert, C., Sehouli, J., Braicu, E. I., Mahner, S., Lambrechts, S., Vergote, I. B., Grimm, C., et al. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-67 · Cited by 20
“As the impact of biomarkers on patients’ survival has been described to vary between histological subtypes [22] only patients with serous histology were included, resulting in a total of 179 serous EOC patients.”
BackgroundSun, P., Jiang, Z., Chen, X., Xue, L., Mao, X., Ruan, G., Song, Y., & Mustea, A. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.5435 · Cited by 20
“An explanation for these differences may be that ovarian carcinoma subtypes exhibit different biological behaviors (3,33).”
Yanagida, S., Anglesio, M. S., Nazeran, T. M., Lum, A. M., Inoue, M., Iida, Y., Takano, H., Nikaido, T., Okamoto, A., & Huntsman, D. D. (2017) · PLoS ONE · doi:10.1371/journal.pone.0178989 · Cited by 20
Self-citationThe proteome of clear cell ovarian carcinoma
Ji, J. X. Y., Cochrane, D. R., Negri, G. L., Colborne, S., Miko, S. E. S., Hoang, L. N., Farnell, D., Tessier‐Cloutier, B., Huvila, J. K., Thompson, E. F., et al. (2022) · The Journal of Pathology · doi:10.1002/path.6006 · Cited by 20
“Epithelial ovarian carcinoma subtypes are being increasingly recognized as different diseases due to their distinct mutational landscape and cells of origin [29].”
BackgroundSelf-citationA cytohistological study of Ki-67 expression in ovarian tumors
Pujani, M., Choudhury, M., & Goyal, S. (2011) · Indian Journal of Pathology and Microbiology · doi:10.4103/0377-4929.77318 · Cited by 20
Rubinsak, L. A., Cohen, C., Khanna, N., Horowitz, I., & Hanley, K. Z. (2016) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000476 · Cited by 20
Wang, J., Liu, Q., Zhou, X., He, Y., Guo, Q., Shi, Q.-L., Eriksson, S., Zhou, J., He, E., & Skog, S. (2017) · Tumor Biology · doi:10.1177/1010428317706479 · Cited by 20
Roberts, D. D., & Lau, L. F. (2010) · Springer eBooks · doi:10.1007/978-3-642-16555-9_11 · Cited by 20
Ruel-Laliberté, J., Kasasni, S. M., Oprea, D., & Viau, M. (2022) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/j.jogc.2022.08.018 · Cited by 19
MetDecode: methylation-based deconvolution of cell-free DNA for noninvasive multi-cancer typing
Passemiers, A., Tuveri, S., Sudhakaran, D., Jatsenko, T., Laga, T., Punie, K., Hatse, S., Tejpar, S., Coosemans, A., Nieuwenhuysen, E. V., et al. (2024) · Bioinformatics · doi:10.1093/bioinformatics/btae522 · Cited by 19
Wang, D., Wang, L., Chen, W., Wang, H., & Liang, C. (2025) · Engineering Applications of Artificial Intelligence · doi:10.1016/j.engappai.2025.110041 · Cited by 19
PPP2R1A mutations cause ATR inhibitor sensitivity in ovarian clear cell carcinoma
Stewart, J., Krastev, D. B., Brough, R., Zatreanu, D. A., Song, F., Baxter, J. S., Sridhar, S., Frankum, J. R., Konde, A., Yang, W. W., et al. (2025) · Oncogene · doi:10.1038/s41388-024-03265-0 · Cited by 19
“Unlike HGSOC, OCCC usually have wild-type (WT) TP53 and a lower frequency of BRCA1 or BRCA2 mutations [7], and presumably a lower frequency of homologous recombination defects, suggesting treatment with platinum salts or PARP inhibitors might not be as widely effective as in HGSOC.”
Differential diagnosis and clinical relevance of ovarian carcinoma subtypes
Conklin, C. M. J., & Gilks, C. B. (2013) · Expert Review of Obstetrics & Gynecology · doi:10.1586/eog.12.72 · Cited by 19
Self-citationWeiss, I., Tropé, C. G., Reich, R., & Davidson, B. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms131012925 · Cited by 19
“OC of different histology is additionally increasingly regarded to represent different diseases with a unique biology and expression profile [13,14].”
Sallum, L. F., Andrade, L. A. L. D. A., da Costa, L. B. E., Ramalho, S., Ferracini, A. C., Natal, R. D. A., Brito, A. B. C., Sarian, L. O., & Derchain, S. (2018) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000001205 · Cited by 19
“Ki67 expression was analyzed for each case, and all colored nucleus were considered positive, independently of the intensity and distribution, performed using a quantitative method with evaluation of the ratio of stained cells compared with the total number of cells in the lesion.(21,22)We used a 1% cutoff value for K…”
MethodIncreased expression of FAK isoforms as potential cancer biomarkers in ovarian cancer
Nolasco‐Quiroga, M., Rosas‐Díaz, M., Moreno, J. G., Godínez-Aguilar, R., L�pez‐Ibarra, M., Piña‐Sánchez, P., Alvarado‐Cabrero, I., Vázquez-Gómez, G., Rocha‐Zavaleta, L., Arenas-Aranda, D. J., et al. (2019) · Oncology Letters · doi:10.3892/ol.2019.10147 · Cited by 19
“The most frequent subtypes are endometrial, clear cells, mucinous and undifferentiated carcinomas (5,7).”
BackgroundMagalhaes, I., Fernebro, J., Own, S. A., Glaessgen, D., Corvigno, S., Remberger, M., Mattsson, J., & Dahlstrand, H. M. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01520-w · Cited by 18
Kshirsagar, M. P., Jiang, W., & Shih, I. (2011) · Journal of Oncology · doi:10.1155/2012/621685 · Cited by 18
“Ovarian carcinomas comprise a diverse group of neoplasms that demonstrate distinct clinicopathological features and unique molecular genetic aberrations with respect to different histologic subtypes [1, 2].”
BackgroundA COEUR cohort study of SATB2 expression and its prognostic value in ovarian endometrioid carcinoma
Page, C. L., Köbel, M., Meunier, L., Provencher, D. M., Mes‐Masson, A., & Rahimi, K. (2019) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.131 · Cited by 18
“Ovarian carcinoma (OC) is the leading cause of mortality from gynecologic malignancy in the Western world and is represented by five histotypes with different molecular characteristics and clinical behaviors [1,2].”
BackgroundSelf-citationPodzielinski, I., Saunders, B. A., Kimbler, K. D., Branscum, A. J., Fung, E. T., DePriest, P. D., van Nagell, J. R., Ueland, F. R., & Baron, A. T. (2013) · Cancer Investigation · doi:10.3109/07357907.2013.789896 · Cited by 18
“, theragnosis) remains an active field of contemporary investigation (12, 13).”
BackgroundNgeow, J. Y. Y., Chiang, J., Astiazarán-Symonds, E., Balmañà, J., Cass, I. A., Kommoss, F. K. F., Foulkes, W. D., James, P. A., Katcher, A. H., Klugman, S. D., et al. (2025) · Genetics in Medicine · doi:10.1016/j.gim.2025.101557 · Cited by 17
Abdallah, B. Y., Horne, S. D., Kurkinen, M. T., Stevens, J. B., Liu, G., Ye, C. J., Barbat, J., Bremer, S. W., & Heng, H. H. (2013) · Systems Biology in Reproductive Medicine · doi:10.3109/19396368.2013.837989 · Cited by 17
“In ovarian cancers, multiple histological subtypes exist, where each subtype exhibits distinct molecular and histological profiles [Dubeau 2008; Kobel et al. 2008; Soslow 2008; Tothill et al. 2008].”
BackgroundXu, T., Vorobyeva, A., Schulga, A. A., Коновалова, Е. В., Vorontsova, O. V., Ding, H., Gräslund, T., Таширева, Л. А., Orlova, A., Максимилианович, Т. В., et al. (2021) · Cancers · doi:10.3390/cancers13163939 · Cited by 17
“The heterogeneity of OC and its chemoresistance have promoted the development of molecular targeted therapies [2,4].”
BackgroundMarjamaa, A., Gibbs, B. E., Kotrba, C., & Masamha, C. P. (2023) · Scientific Reports · doi:10.1038/s41598-023-44548-y · Cited by 19
Gitlin‐Domagalska, A., Dębowski, D., Łęgowska, A., Stirnberg, M., Okońska, J., Gütschow, M., & Rolka, K. (2017) · Biopolymers · doi:10.1002/bip.23031 · Cited by 17
The heterogeneity of epithelial ovarian cancer: Getting it right
Gershenson, D. M. (2010) · Cancer · doi:10.1002/cncr.24926 · Cited by 17
“genes and pathways involved in the pathogenesis of mucinous and clear cell carcinomas compared with high-grade serous carcinomas.(16) Importantly, all 3 tumor types—low-grade serous, mucinous, and clear cell—appear to be relatively resistant to taxane/platinum-based chemotherapy.”
BackgroundWang, Y., Farnell, D., Farahani, H., Nursey, M., Tessier‐Cloutier, B., Jones, S. J. M., Huntsman, D. D., Gilks, C. B., & Bashashati, A. (2020) · arXiv (Cornell University) · doi:10.48550/arxiv.2005.10957 · Cited by 17
Self-citationMendiola, M., Redondo, A., Heredia-Soto, V., Herránz, J., Berjón, A., Hernández, A., Miguel-Martín, M., Crespo, R., Barriuso, J., Cruz, P., et al. (2018) · Anticancer Research · doi:10.21873/anticanres.12869 · Cited by 16
Sganga, S., Riondino, S., Iannantuono, G. M., Rosenfeld, R., Roselli, M., & Torino, F. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13091339 · Cited by 17
“SGN-75 is a humanized anti-CD70 IgG1 monoclonal antibody, h1F6, also known as SGN-70, chemically conjugated to monomethyl auristatin F (MMAF), a synthetic analog of the natural microtubule-destroying agent, dolastatin 10, via a maleimidocaproyl (mc) [36,49].”
BackgroundClinicopathologic Analysis of Low-stage Sporadic Ovarian Carcinomas: A Reappraisal
Karamurzin, Y. S., Leitão, M. M., & Soslow, R. A. (2013) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e318272ff19 · Cited by 16
“7 (4-170) Site of recurrence Vagina/pelvis 12 (41.”
Proteomic Profiling in Ovarian Cancer
Kim, G., Minig, L., & Kohn, E. C. (2009) · International Journal of Gynecological Cancer · doi:10.1111/igc.0b013e3181c03929 · Cited by 16
“Köbel et al have retrospectively studied 21 candidate tissue biomarkers in a cohort of 500 women without residual tumor after primary cytoreduction.(17) The authors evaluated these 21 prospective biomarkers with tissue microarray immunohistochemical analysis.”
BackgroundMa, J., To, S. K. Y., Fung, K. S. W., Wang, K., Zhang, J., Ngan, A. H. W., Yung, S., Chan, T. M., Wong, C. C., Ip, P. P. C., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.115096 · Cited by 16
Yamanouchi, K., Ohta, T., Liu, Z., Oji, Y., Sugiyama, H., Shridhar, V., Matsumura, S., Takahashi, T., Takahashi, K., & Kurachi, H. (2014) · Translational Oncology · doi:10.1016/j.tranon.2014.07.008 · Cited by 15
“In ovarian cancer, WT1 is highly expressed in high-grade serous carcinoma, a more aggressive subtype [16].”
Background
Metadata
- Authors
- Köbel, M., Kalloger, S. E., Boyd, N., McKinney, S., Mehl, E., Palmer, C., Leung, S., Bowen, N. J., Ionescu, D. N., Rajput, A., Prentice, L. M., Miller, D., Santos, J., Swenerton, K., Gilks, C. B., & Huntsman, D.
- Affiliations
- BC Cancer Agency (CA)
- Canary Foundation (US)
- Georgia Institute of Technology (US)
- Corresponding author
- Huntsman, David
- ORCID
- Venue
- PLoS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2008-12-02
- Volume
- 5
- Issue
- 12
- Pages
- e232
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- PMC
- PMC2592352
- OpenAlex
- W2129355295
- Cited by
- 814
- References
- 40
- Citations by year
- 2026: 16 · 2025: 29 · 2024: 30 · 2023: 43 · 2022: 34 · 2021: 37 · 2020: 39 · 2019: 33 · 2018: 50 · 2017: 44 · 2016: 60 · 2015: 42 · 2014: 60 · 2013: 71 · 2012: 70
- FWCI
- 59.86
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Eli Lilly and Company
- Sanofi
- Canary Foundation
- Michael Smith Health Research BC
- Eli Lilly Canada
- Canadian Institutes of Health Research (017051)
- National Cancer Institute
- Topics
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Keywords
- ovarian carcinoma, histological subtypes, high-grade serous carcinoma, clear cell carcinoma, endometrioid carcinoma, mucinous carcinoma, tumor markers, prognostic factors, Ki-67, WT1, CA125, HE4, stage at diagnosis, survival, molecular pathogenesis, tumor cell proliferation
- MeSH terms
- Carcinoma, Diagnosis, Differential, Female, Follow-Up Studies, Humans, Middle Aged, Neoplasm Staging, Ovarian Diseases, Ovarian Neoplasms, Prognosis, Retrospective Studies, Biomarkers, Tumor, Cohort Studies, Confounding Factors, Epidemiologic, Survival Analysis, Tissue Array Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.